Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1981 Oct;18(5):325–330. doi: 10.1136/jmg.18.5.325

Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution.

A K Karim, M S Elfellah, D A Evans
PMCID: PMC1048751  PMID: 7328611

Abstract

Acetylator phenotyping by means of a sulphadimidine tests revealed 65% of Libyan Arabs to be slow acetylators. Hence the frequency of the allele controlling slow acetylation (As) is estimated as q = 0.81 +/- 0.05. This estimate is similar to those previously recorded in European and adjacent Middle Eastern populations.

Full text

PDF
325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMSTRONG A. R., PEART H. E. A comparison between the behavior of Eskimos and non-Eskimos to the administration of isoniazid. Am Rev Respir Dis. 1960 Apr;81:588–594. doi: 10.1164/arrd.1960.81.4.588. [DOI] [PubMed] [Google Scholar]
  2. BARTMANN K., MASSMANN W. [The blood level of INH in adults and children]. Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1960;122:239–250. [PubMed] [Google Scholar]
  3. DEVADATTA S., GANGADHARAM P. R., ANDREWS R. H., FOX W., RAMAKRISHNAN C. V., SELKON J. B., VELU S. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587–598. [PMC free article] [PubMed] [Google Scholar]
  4. DUFOUR A. P., KNIGHT R. A., HARRIS H. W. GENETICS OF ISONIAZID METABOLISM IN CAUCASIAN, NEGRO, AND JAPANESE POPULATIONS. Science. 1964 Jul 24;145(3630):391–391. [PubMed] [Google Scholar]
  5. De March Ayuela P., Noguera García J. Metabolismo de la isoniazida. I. Aspecto antropológico. Rev Clin Esp. 1966 Jul 15;102(1):32–41. [PubMed] [Google Scholar]
  6. Eidus L., Glatthaar E., Hodgkin M. M., Nel E. E., Kleeberg H. H. Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks. Int J Clin Pharmacol Biopharm. 1979 Jul;17(7):311–316. [PubMed] [Google Scholar]
  7. Eidus L., Hodgkin M. M., Schaefer O., Jessamine A. G. Distribution of isoniazid inactivators determined in Eskimos and Canadian college students by a urine test. Rev Can Biol. 1974 Jun;33(2):117–123. [PubMed] [Google Scholar]
  8. Ellard G. A., Gammon P. T. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol. 1977 Feb;4(1):5–14. doi: 10.1111/j.1365-2125.1977.tb00659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ellard G. A., Gammon P. T., Polansky F., Víznerová A., Havlík I., Fox W. Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis. Tubercle. 1973 Mar;54(1):57–66. doi: 10.1016/0041-3879(73)90015-9. [DOI] [PubMed] [Google Scholar]
  10. Ellard G. A., Gammon P. T., Tiitinen H. Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid to acid-labile isoniazid: a study in Finnish Lapland. Tubercle. 1973 Sep;54(3):201–210. doi: 10.1016/0041-3879(73)90025-1. [DOI] [PubMed] [Google Scholar]
  11. Ellard G. A., Gammon P. T., Titinen H. Determination of the acetylator phenotype using matrix isoniazid. Tubercle. 1975 Sep;56(3):203–209. doi: 10.1016/0041-3879(75)90053-7. [DOI] [PubMed] [Google Scholar]
  12. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Evans D. A., Bullen M. F., Houston J., Hopkins C. A., Vetters J. M. Antinuclear factor in rapid and slow acetylator patients treated with isoniazid. J Med Genet. 1972 Mar;9(1):53–56. doi: 10.1136/jmg.9.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Eze L. C., Evans D. A. The use of the autoanalyzer to determine the acetylator phenotype. J Med Genet. 1972 Mar;9(1):57–59. doi: 10.1136/jmg.9.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Eze L. C., Obidoa O. Acetylation of sulfamethazine in a Nigerian population. Biochem Genet. 1978 Dec;16(11-12):1073–1077. doi: 10.1007/BF00484527. [DOI] [PubMed] [Google Scholar]
  16. Fawcett I. W., Gammon P. T. Determination of the acetylator phenotype in a Northern Nigerian population. Tubercle. 1975 Sep;56(3):199–201. doi: 10.1016/0041-3879(75)90052-5. [DOI] [PubMed] [Google Scholar]
  17. Frislid K., Berg M., Hansteen V., Lunde P. K. Comparison of the acetylation of procainamide and sulfadimidine in man. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):433–438. doi: 10.1007/BF00606561. [DOI] [PubMed] [Google Scholar]
  18. GANGADHARAM P. R., BHATIA A. L., RADHAKRISHNA S., SELKON J. B. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. Bull World Health Organ. 1961;25:765–777. [PMC free article] [PubMed] [Google Scholar]
  19. GOW J. G., EVANS D. A. A STUDY OF THE INFLUENCE OF THE ISONIAZID INACTIVATOR PHENOTYPE ON REVERSION IN GENITO-URINARY TUBERCULOSIS. Tubercle. 1964 Jun;45:136–143. doi: 10.1016/s0041-3879(64)80071-4. [DOI] [PubMed] [Google Scholar]
  20. Goedde H. W., Benkmann H. G., Agarwal D. P. Genetic studies in Ecuador: acetylator phenotypes, red cell enzyme and serum protein polymorphisms of Shuara Indians. Am J Phys Anthropol. 1977 Nov;47(3):419–425. doi: 10.1002/ajpa.1330470313. [DOI] [PubMed] [Google Scholar]
  21. Goedde H. W., Flatz G., Rahimi A. G., Kaifie S., Benkmann H. G., Kriese G., Delbrück H. The acetylator polymorphism in four populations of Afghanistan. Hum Hered. 1977;27(5):383–388. doi: 10.1159/000152896. [DOI] [PubMed] [Google Scholar]
  22. Hanngren A., Borgå O., Sjöqvist F. Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS). Scand J Respir Dis. 1970;51(1):61–69. [PubMed] [Google Scholar]
  23. Hashem N., Khalifa S., Nour A. The frequency of isoniazid acetylase enzyme deficiency among Egyptians. Am J Phys Anthropol. 1969 Jul;31(1):97–101. doi: 10.1002/ajpa.1330310114. [DOI] [PubMed] [Google Scholar]
  24. Hodgkin M. M., Eidus L., Bailey W. C. Isoniazid phenotyping of black as well as white patients. Can J Physiol Pharmacol. 1979 Jul;57(7):760–763. doi: 10.1139/y79-117. [DOI] [PubMed] [Google Scholar]
  25. Hoo J. J., Hussein L., Goedde H. W. A simplified micromethod for the determination of the acetylator phenotype. J Clin Chem Clin Biochem. 1977 Jun;15(6):329–331. doi: 10.1515/cclm.1977.15.1-12.329. [DOI] [PubMed] [Google Scholar]
  26. Jeanes C. W., Schaefer O., Eidus L. Inactivation of isoniazid by Canadian Eskimos and Indians. Can Med Assoc J. 1972 Feb 19;106(4):331–335. [PMC free article] [PubMed] [Google Scholar]
  27. Jenkins T., Lehmann H., Nurse G. T. Public health and genetic constitution of the San ("Bushmen"): carbohydrate metabolism and acetylator status of the Kung of Tsumkwe in the North-western Kalahari. Br Med J. 1974 Apr 6;2(5909):23–26. doi: 10.1136/bmj.2.5909.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Karim A. K., Evans D. A. Polymorphic acetylation of nitrazepam. J Med Genet. 1976 Feb;13(1):17–19. doi: 10.1136/jmg.13.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. LEHIR M., CHICOU J., HETRICK G., MERCIER A., NEEL R., RIST N. ESSAI CLINIQUE CONTR OL'E DE TROIS TYPES DE TRAITEMENT ORAL DE LA TUBERCULOSE PULMONAIRE. (ISONIAZIDE + ETHIONAMIDE, ISONIAZIDE + PAS, ISONIAZIDE SEUL) Bull World Health Organ. 1964;30:701–732. [PMC free article] [PubMed] [Google Scholar]
  30. Mattila M. J., Tiitinen H. The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients. Ann Med Exp Biol Fenn. 1967;45(4):423–427. [PubMed] [Google Scholar]
  31. Molin L., Larsson R., Karlsson E. Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand. 1977;201(3):217–222. doi: 10.1111/j.0954-6820.1977.tb15685.x. [DOI] [PubMed] [Google Scholar]
  32. Peters J. H., Gordon G. R., Ghoul D. C., Tolentino J. G., Walsh G. P., Levy L. The diposition of the antileprotic drug dapsone (DDS) in Philippine subjects. Am J Trop Med Hyg. 1972 Jul;21(4):450–457. doi: 10.4269/ajtmh.1972.21.450. [DOI] [PubMed] [Google Scholar]
  33. Peters J. H., Gordon G. R., Karat A. B. Polymorphic acetylation of the antibacterials, sulfamethazine and dapsone, in South Indian subjects. Am J Trop Med Hyg. 1975 Jul;24(4):641–648. doi: 10.4269/ajtmh.1975.24.641. [DOI] [PubMed] [Google Scholar]
  34. Raghupati Sarma G., Kailasam S., Kannapiran M., Krishnaswami K. V., Thomas L., Nair N. G., Narayana A. S. Classification of subjects as slow or rapid inactivators of isoniazid based on the ratio of acetylisoniazid to isoniazid in urine determined by a simple colorimetric method. Indian J Med Res. 1976 Oct;64(10):1456–1461. [PubMed] [Google Scholar]
  35. Rao K. V., Mitchison D. A., Nair N. G., Prema K., Tripathy S. P. Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J. 1970 Aug 29;3(5721):495–497. doi: 10.1136/bmj.3.5721.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. SUNAHARA S., URANO M. LES PROBL'EMES DU M'ETABOLISME DE L'ISONIAZIDE. CARACT'ERE H'ER'EDITAIRE ET VARIABILIT'E SUIVANT LES RACES. Med Thorac. 1963;20:289–312. [PubMed] [Google Scholar]
  37. SUNAHARA S., URANO M., LIN H. T., CHEG T. J., JARUMILINDA A. FURTHER OBSERVATIONS ON TRIMODALITY OF FREQUENCY DISTRIBUTION CURVE OF BIOLOGICALLY ACTIVE ISONIAZID BLOOD LEVELS AND "CLINE" INFREQUENCIES OF ALLELES CONTROLLING ISONIAZID INACTIVATION. Acta Tuberc Pneumol Scand. 1963;43:181–195. [PubMed] [Google Scholar]
  38. Schröder H., Evans D. A. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972 Apr;13(4):278–284. doi: 10.1136/gut.13.4.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schröder H., Evans D. A. The polymorphic acetylation of sulphapyridine in man. J Med Genet. 1972 Jun;9(2):168–171. doi: 10.1136/jmg.9.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Scott E. M., Wright R. C., Weaver D. D. The discrimination of phenotypes for rate of disappearance of isonicotinoyl hydrazide from serum. J Clin Invest. 1969 Jul;48(7):1173–1176. doi: 10.1172/JCI106081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Smith S. E., Kyi T. Inactivation of isoniazid in Burmese subjects. Nature. 1968 Mar 30;217(5135):1273–1273. doi: 10.1038/2171273a0. [DOI] [PubMed] [Google Scholar]
  42. Tiitinen H. Isoniazid and ethionamide serum levels and inactivation in Finnish subjects. Scand J Respir Dis. 1969;50(2):110–124. [PubMed] [Google Scholar]
  43. Tiitinen H. Isoniazid inactivation status and the development of chronic tuberculosis. Scand J Respir Dis. 1969;50(3):227–234. [PubMed] [Google Scholar]
  44. Víznerová A., Slavíková Z., Ellard G. A. The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. Tubercle. 1973 Mar;54(1):67–71. doi: 10.1016/0041-3879(73)90016-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES